Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Summary of Disaggregated Amounts that Comprise Research and Development Expenses

In addition to the significant expense categories included within net loss presented on the statements of operations and comprehensive loss, see below for disaggregated amounts that comprise research and development expenses:

	Year Ended
	December 31,
	2024		2023
External research and development expenses:
Clinical trials expenses	$	15,626	$	21,200
Consulting and outside services		4,707		4,770
Other external research and development (1)		6,911		12,340
Total external research and development expenses		27,244		38,310
Internal research and development expenses:
Personnel related expenses		13,244		16,561
Total research and development expenses	$	40,488	$	54,871

(1) Chemistry manufacturing controls, research and preclinical studies and other miscellaneous expenses.